GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19)
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Phase I study to assess the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine
given as a booster to those previously vaccinated against SARS-CoV-2